Volume 8, Issue 5

Newer NNRTI Agents for ART

In this issue:

When is it appropriate to include an NNRTI (non-nucleoside reverse transcriptase inhibitor) like rilpivirine or doravirine in an ART regimen? What do the guidelines say? What’s known about patient selection criteria? Food requirements, dosing schedules, potential drug-drug interactions, and the currently known risk factors for developing resistance? What are the most important things clinicians need to know before considering either agent for any particular patient?

These are some of the questions Drs. Darcy Wooten and Michael Tang from the from the Division of Infectious Disease at the University of California, San Diego, address in this issue of eHIV Review.

Learning objectives:

  • Describe the risk factors associated with virologic failure with long-acting injectable cabotegravir and rilpivirine.
  • Explain the weight and metabolic effects of doravirine compared to other ARVs. 

Authors:

Darcy Wooten, MD
Darcy Wooten, MD

Associate Professor of Medicine
University of California, San Diego
La Jolla, CA

Michael Tang, MD
Michael Tang, MD

Assistant Professor of Medicine
University of California, San Diego
La Jolla, CA

Program Directors:

Ethel D. Weld, MD, PhD

Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
Baltimore, Maryland
(she/her/hers)

Matthew Spinelli, MD, MAS

Assistant Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, California
(he/him/his)

Justin Alves, RN, FNP-BC, ACRN, CARN, CNE

Nurse Educator
Boston Medical Center
Boston, MA
(he/him/his)

Launch date: May 17, 2023
Expiration date: May 16, 2025